Category: Clinical Trial News

We are excited to announce that Dr. Rebecca Traub, Principal Investigator at The University of North Carolina, has been selected to receive an award from the Charcot-Marie-Tooth Association (CMTA) to support research within the Inherited Neuropathy Consortium (INC). The INC is a collaborative network of academic medical centers, patient advocacy...

Chapel Hill, NC — September 30, 2025 — We are proud to announce that Dr. Clio Rubinos has been awarded the prestigious Annual Zeto Clinical Trial Sponsorship Program for her pioneering research project focused on the use of continuous EEG in Zambia. Dr. Rubinos will lead the PRECISE-Z Study (Pilot...

Dr. James F. Howard Jr., Professor of Neurology at the University of North Carolina at Chapel Hill School of Medicine, has played a pivotal role as Principal Investigator in the ADAPT SERON study—marking a major advancement in the treatment of generalized myasthenia gravis (gMG). The study, conducted by global immunology...

In May 2022, Yael Shiloh-Malawsky, MD, a neurologist at the UNC School of Medicine, met two new patients combatting a rare and fatal neurodegenerative disorder called Batten disease. With help from UNC, the twin girls were able to get personalized treatment from bench to bedside in record time.

The Department of Neurology is pleased to welcome Christopher Hilliard, BS, CCRC to the position of NCTU Director. Chris will join the department of Neurology with 10 years of experience in clinical research trials, training, mentoring, and leading large research teams. In his previous role, Chris served as the Assistant Director of Clinical Operations...

Press Release Courtesy of EIN Presswire and Ad Scientiam. The ME&MGopen study has already recruited 165 patients in the USA and 11 in Canada. This innovative program is supported by Alexion, AstraZeneca Rare Disease. PARIS, FRANCE, September 21, 2023 /EINPresswire.com/ — Generalized Myasthenia Gravis (gMG) is a chronic autoimmune neuromuscular...

Are you interested in advancing treatments in Parkinson’s disease? Did you know that the non-motor symptoms of Parkinson’s disease are often very disabling and can lead to poor outcomes with the disease? If you have Parkinson’s disease, you may be eligible to take part in a research study to learn...

This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of CBD administered as ZYN002, a transdermal gel, for the treatment of children and adolescent patients with FXS. Status: Not currently enrolling

A study is being conducted to understand the effectiveness of ALXN2050 compared with placebo in the treatment of generalized MG (gMG) based on improvement in the Myasthenia Gravis Activities of Daily Living (MG-ADL) total score. Status: Open

This is a genetic registry study aimed at developing a central location to store Parkinson’s Disease genetic data for future research use. Status: Open